THURSDAY, March 4 (HealthDay News) -- Rosuvastatin (Crestor) reduces all-cause mortality and the incidence of first cardiovascular events among subjects with moderate chronic kidney disease (CKD), low-density lipoprotein cholesterol (LDL-C) of less than 130 mg/dL, and elevated high-sensitivity C-reactive protein (hsCRP), according to research published online March 3 in the Journal of the American College of Cardiology.
Paul M Ridker, M.D., of Brigham and Women's Hospital in Boston, and colleagues assembled data on subjects with moderate CKD who participated in the Justification for the Use of Statins in Prevention -- an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial that compared the statin and a placebo in subjects without cardiovascular disease who had LDL-C of less than 130 mg/dL and hsCRP at or above 2 mg/L. The researchers compared cardiovascular and mortality outcomes in the CKD group to the non-CKD group over a median follow-up of 1.9 years.
Overall, the researchers found that the subjects with moderate CKD had a greater risk of vascular events (hazard ratio, 1.54) than subjects without CKD. Those with moderate CKD taking rosuvastatin had a 44 percent decrease in all-cause mortality and a 45 percent reduction in risk for myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization, or cardiovascular death. Median LDL-C, hsCRP, and rosuvastatin side effects were similar for those with and without CKD.
"As such, these data support guidelines from the American Heart Association and the National Kidney Foundation to provide more aggressive cardiovascular prevention efforts among those with mild to moderately reduced renal function," the authors write.
JUPITER was supported by AstraZeneca. Several authors reported financial relationships with the pharmaceutical industry, including AstraZeneca.
Abstract
Full Text
